Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct;120(1):1-10.
doi: 10.1016/j.jdermsci.2025.08.002. Epub 2025 Aug 19.

Risankizumab differentially modulates circulating T-cell populations in psoriasis according to autoreactivity status

Rebecca Favaro  1 , Paola Facheris  2 , Alessandra Formai  1 , Luigi Gargiulo  1 , Luciano Ibba  1 , Giovanni Fiorillo  1 , Roberta Valeria Latorre  1 , Jessica Avagliano  1 , Alessandra Narcisi  1 , Giampiero Girolomoni  3 , Santo Raffaele Mercuri  4 , Antonio Costanzo  5
Affiliations

Risankizumab differentially modulates circulating T-cell populations in psoriasis according to autoreactivity status

Rebecca Favaro et al. J Dermatol Sci. 2025 Oct.

Abstract

Background: In a recent paper, our group described that the presence of double autoreactivity to both LL37 and ADAMTSL5 autoantigens in psoriatic patients decreased the clinical responses to risankizumab, but how this influences the changes in the peripheral inflammatory T-cell populations is still unknown.

Objective: This study aims to evaluate how risankizumab modulates the circulating inflammatory T-cell populations in psoriatic patients and, specifically, in autoreactive subjects.

Methods: The presence of LL37- and ADAMTSL5-reactive circulating T-cells was assessed in a cohort of 142 psoriatic patients, and 87 demonstrated autoreactivity at baseline. Patients were treated with risankizumab for 52 weeks, and specific T-cell populations were analyzed at different timepoints.

Results: The frequency of Ki67+CD4+, Ki67+CD8+ T-cells, CD8+IL-17+ and CD8+IL-22+ T-cells showed a positive correlation with baseline PASI and decreased with treatment. Notably, CD8+IL-17+ T-cells decreased both in single-LL37 and single-ADAMTSL5-reactive subjects, but not in subjects that showed autoreactivity to both autoantigens. LL37 autoreactivity of CD4+ and CD8+ T-cells decreased with treatment, but not for CD4+ in double-reactive subjects. While Treg frequency negatively correlated with baseline PASI and increased within 16 weeks of treatment, significantly decreasing the IL-17+CD4+/Treg ratio over time, Treg modulation was not evident in double-reactive subjects. Interestingly, the subpopulations of CD8+MAIT IL-17+ and CD3+MAIT IL-22+ cells, involved also in psoriatic arthritis, decreased in treated subjects following IL-23 inhibition.

Conclusion: Rizankizumab efficiently decreases the circulating inflammatory T-cell populations and modulates Tregs' plasticity in single-LL37- or single-ADAMTSL5-reactive subjects, but not in double-reactive subjects.

Keywords: ADAMTSL5; LL37; autoantigens; autoreactivity; biomarkers; psoriasis.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest R. Favaro A. Formai, R. V. Latorre, J. Avagliano, have no conflict of interest to declare. G. Fiorillo has served as advisory board member for Novartis. P. Facheris has served as a consultant for Eli Lilly and as a speaker for UCB, Abbvie, and Pfizer. L. Gargiulo has served as advisory board member for Abbive, Almirall, Amgen, Eli-Lilly, Leo-Pharma, Sanofi, Novartis, UCB. I. Ibba served as consultants for Almirall. A. Narcisi has served on advisory boards, received honoraria for lectures and research grants from Almirall, Abbvie, Leo Pharma, Celgene, Eli Lilly, Janssen, Novartis, Sanofi Genzyme, Amgen and Boehringer Ingelheim. G. Girolomoni served as consultant and/or speaker for AbbVie, Almirall, Bristol-Meyers Squibb (BMS), Eli-Lilly, LeoPharma, Novartis, Pfizer, Samsung, Sanofi. S. R. Mercuri has served as advisory board member, consultant and speaker for Abbvie, Almirall, Amgen, Leo-Pharma, Eli-Lilly, Janssen, Novartis, Pfizer, Bristol-Meyer Squibb, Sanofi Genzyme, UCB. A. Costanzo has served as an advisory board member, consultant and has received fees and speaker’s honoraria or has participated in clinical trials for Abbvie, Almirall, Biogen, LEO Pharma, Eli-Lilly, Janssen, Novartis, Pfizer, Sanofi Genzyme and UCB.

MeSH terms